铂类抗肿瘤药物耐药机制的研究进展和应对策略

R979.1; 铂类抗肿瘤药物是目前临床应用最广泛的一线化疗药物,疗效显著.但临床使用过程中出现的非小细胞肺癌、乳腺癌、卵巢癌等铂类药物耐药问题,严重影响了铂类药物的疗效,也极大限制了铂类药物的使用.铂类药物耐药是由多种因素引起的,目前关于铂类药物的耐药机制主要有以下几个方面:减少细胞内铂的积累、促进细胞内铂的失活、DNA的损伤修复能力增强、肿瘤细胞凋亡抑制作用增强等.本文就铂类抗肿瘤药物的耐药机制和应对策略做一综述,为铂类抗肿瘤药物的研发提供思路,为克服临床铂类药物耐药问题提供参考....

Full description

Saved in:
Bibliographic Details
Published in药学实践杂志 Vol. 40; no. 4; pp. 302 - 308
Main Authors 王冬博, 聂晶, 武慧娜, 孙磊, 刘丽慧, 吴记勇
Format Journal Article
LanguageChinese
Published 山东省第二人民医院药学部, 山东 济南 250022 2022
Subjects
铂类药物
抗肿瘤药物
耐药机制
Online AccessGet full text

Cover

Abstract R979.1; 铂类抗肿瘤药物是目前临床应用最广泛的一线化疗药物,疗效显著.但临床使用过程中出现的非小细胞肺癌、乳腺癌、卵巢癌等铂类药物耐药问题,严重影响了铂类药物的疗效,也极大限制了铂类药物的使用.铂类药物耐药是由多种因素引起的,目前关于铂类药物的耐药机制主要有以下几个方面:减少细胞内铂的积累、促进细胞内铂的失活、DNA的损伤修复能力增强、肿瘤细胞凋亡抑制作用增强等.本文就铂类抗肿瘤药物的耐药机制和应对策略做一综述,为铂类抗肿瘤药物的研发提供思路,为克服临床铂类药物耐药问题提供参考.
AbstractList R979.1; 铂类抗肿瘤药物是目前临床应用最广泛的一线化疗药物,疗效显著.但临床使用过程中出现的非小细胞肺癌、乳腺癌、卵巢癌等铂类药物耐药问题,严重影响了铂类药物的疗效,也极大限制了铂类药物的使用.铂类药物耐药是由多种因素引起的,目前关于铂类药物的耐药机制主要有以下几个方面:减少细胞内铂的积累、促进细胞内铂的失活、DNA的损伤修复能力增强、肿瘤细胞凋亡抑制作用增强等.本文就铂类抗肿瘤药物的耐药机制和应对策略做一综述,为铂类抗肿瘤药物的研发提供思路,为克服临床铂类药物耐药问题提供参考.
Author 王冬博
武慧娜
吴记勇
孙磊
聂晶
刘丽慧
AuthorAffiliation 山东省第二人民医院药学部, 山东 济南 250022
AuthorAffiliation_xml – name: 山东省第二人民医院药学部, 山东 济南 250022
Author_FL SUN Lei
WANG Dongbo
WU Jiyong
LIU Lihui
NIE Jing
WU Huina
Author_FL_xml – sequence: 1
  fullname: WANG Dongbo
– sequence: 2
  fullname: NIE Jing
– sequence: 3
  fullname: WU Huina
– sequence: 4
  fullname: SUN Lei
– sequence: 5
  fullname: LIU Lihui
– sequence: 6
  fullname: WU Jiyong
Author_xml – sequence: 1
  fullname: 王冬博
– sequence: 2
  fullname: 聂晶
– sequence: 3
  fullname: 武慧娜
– sequence: 4
  fullname: 孙磊
– sequence: 5
  fullname: 刘丽慧
– sequence: 6
  fullname: 吴记勇
BookMark eNrjYmDJy89LZWBQNjTQMzQyMjDTz9LLLC7O0zM0MDDTNTA0NNQzMgCKmxiYmLEwcMJFORh4i4szkwxMDY3NTU0NLTgZ7F9Obnq-cfezrukvmvY_n7HkRe_6550rXzRMADKezdn1tGPb81ktzxdMeb5y24v9s59unPp0Us_TXVOert_5fO2051OX8jCwpiXmFKfyQmluBnU31xBnD93yxLy0xLz0-Kz80qI8oEx8ZUVxVlUV1FkGxsbEqwQAYzlbtA
ClassificationCodes R979.1
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.12206/j.issn.1006-0111.202204046
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Research progress and coping strategy of the drug resistant mechanism of platinum anti-tumor drugs
EndPage 308
ExternalDocumentID yxsjzz202204003
GrantInformation_xml – fundername: 山东省医药卫生科技发展计划项目
  funderid: (202113010614)
GroupedDBID 2B.
4A8
92I
93N
ALMA_UNASSIGNED_HOLDINGS
CDYEO
PSX
TCJ
ID FETCH-wanfang_journals_yxsjzz2022040033
ISSN 1006-0111
IngestDate Wed Nov 06 04:21:32 EST 2024
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords 铂类药物
抗肿瘤药物
耐药机制
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-wanfang_journals_yxsjzz2022040033
ParticipantIDs wanfang_journals_yxsjzz202204003
PublicationCentury 2000
PublicationDate 2022
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – year: 2022
  text: 2022
PublicationDecade 2020
PublicationTitle 药学实践杂志
PublicationTitle_FL Journal of Pharmaceutical Practice
PublicationYear 2022
Publisher 山东省第二人民医院药学部, 山东 济南 250022
Publisher_xml – name: 山东省第二人民医院药学部, 山东 济南 250022
SSID ssib051375518
ssib006562796
ssib000270657
ssib050280699
ssib001104385
ssib036440809
Score 4.6081047
Snippet R979.1;...
SourceID wanfang
SourceType Aggregation Database
StartPage 302
Title 铂类抗肿瘤药物耐药机制的研究进展和应对策略
URI https://d.wanfangdata.com.cn/periodical/yxsjzz202204003
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NaxNREH_UFMSLKCp-E9DBQ0lMdt_bfe8kbzcbiqCnCr2VTTYqHiLYFDQnKR5UFERbFe3Bgx56kNJLwXroX5Nu_C-cmd0kS1upCmEZ5s2b37wZdmfefkyEuKpwk9yOsXJLHB1XJApVWp1au9L2Xdd3OzKu879E3Lrtzd6RN-fV_NSRtcJbS0u9VrXdP_C7kv-JKvIwrvSV7D9EdqwUGUhjfPGIEcbjX8UYIgPGBe1A5ENQhyCAyANtwfgQaeIHTRoyGqxkTgMsc7QBa5hDLzoUhjwwIQQWIgVaQ-DxdAtaEmFROCMMD2nSbwISRnSjiDAO6JA5loUVqQ0Mz2qAyRQiUxXL4oIBisSsx0QEJmIUXJ1i2xq8WMW44wzKC4pAsyHaA8v4qM_YiQgC1HkyaiHrJyPeCBFdh6A-Q2v0w0SEjTLZItDftnivxJnsqXNH4C-SEJAKXm1I0DQ1ZNMkuUaPCPK1BwF6ts5WhxxFQ2jWOcgvBrRL9uG5sR9vhpUpckfuAn8Gy8-RkVn2yW7v5NknT09ZN6v8NJSFXOPWnELZ4nJ7jP0Z0XFqHqdEQqiOEarkHryAyz19yLmyefJ48UG_n0tQK91pBy_jqiSmbdAImsWn1rXiU3MsJaVb6IWEewWn0M7R9ejvzSft4hQ_1p9sh1Xd9alBIL-gkNt5VFwZreL6n9fAX9x178bde4XicO6EOJ7v6so2O0VPiqn-_VPixq93y-nmz92XH4bLO-nHr8PXG-mL9eHTN0jsrm0Pnm-ln56lX1bS9a3hzufB5urg7avB9spg40f6_X26-u20uNaM5sLZSg66kF8TFhf2eM49I0rdh93OWVFuySRxVNJWppZIqZK406q1EyU9J64b5fvnRPkwbecPF7kgjhGd3SO8KEq9R0udS1g191qX8-D9BjlwksY
link.rule.ids 315,783,787,4031,27935,27936,27937
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%93%82%E7%B1%BB%E6%8A%97%E8%82%BF%E7%98%A4%E8%8D%AF%E7%89%A9%E8%80%90%E8%8D%AF%E6%9C%BA%E5%88%B6%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95%E5%92%8C%E5%BA%94%E5%AF%B9%E7%AD%96%E7%95%A5&rft.jtitle=%E8%8D%AF%E5%AD%A6%E5%AE%9E%E8%B7%B5%E6%9D%82%E5%BF%97&rft.au=%E7%8E%8B%E5%86%AC%E5%8D%9A&rft.au=%E8%81%82%E6%99%B6&rft.au=%E6%AD%A6%E6%85%A7%E5%A8%9C&rft.au=%E5%AD%99%E7%A3%8A&rft.date=2022&rft.pub=%E5%B1%B1%E4%B8%9C%E7%9C%81%E7%AC%AC%E4%BA%8C%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E8%8D%AF%E5%AD%A6%E9%83%A8%2C+%E5%B1%B1%E4%B8%9C+%E6%B5%8E%E5%8D%97+250022&rft.issn=1006-0111&rft.volume=40&rft.issue=4&rft.spage=302&rft.epage=308&rft_id=info:doi/10.12206%2Fj.issn.1006-0111.202204046&rft.externalDocID=yxsjzz202204003
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fyxsjzz%2Fyxsjzz.jpg